DN
David Nierengarten Wedbush Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Xencor
XNCR
$597M
| $8.37 | $26 |
211%
upside
| Outperform | 2 days ago |
|
|
TLX
2
Telix Pharmaceuticals Limited American Depositary Shares
TLX
$3.13B
| $9.08 | $22 |
142%
upside
| Outperform | 7 days ago |
|
|
BBOT
3
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$798M
| $10.08 | $25 |
148%
upside
| Outperform | 17 days ago |
|
4
argenx
ARGX
$44.9B
| $733.66 | $715 |
3%
downside
| Outperform | 2 months ago |
|
5
Perspective Therapeutics
CATX
$263M
| $3.54 | $11 |
211%
upside
| Outperform | 2 months ago |
|
6
Nuvation Bio
NUVB
$1.17B
| $3.42 | $5 |
46%
upside
| Outperform | 2 months ago |
|
7
Intellia Therapeutics
NTLA
$1.25B
| $11.62 | $10 |
14%
downside
| Neutral | 3 months ago |
|
8
NovoCure
NVCR
$1.34B
| $11.98 | $27 |
125%
upside
| Neutral | 4 months ago |
|
9
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $35.51 | $34 |
4%
downside
| Outperform | 4 months ago |
|
10
Immunome
IMNM
$853M
| $9.80 | $33 |
237%
upside
| Outperform | 5 months ago |
|
|
BCAX
11
Bicara Therapeutics Inc. Common Stock
BCAX
$658M
| $12.06 | $31 |
157%
upside
| Outperform | 6 months ago |
|
12
AnaptysBio
ANAB
$590M
| $21.09 | $40 |
90%
upside
| Outperform | 6 months ago |
|
13
Apogee Therapeutics
APGE
$2.21B
| $37.13 | $90 |
142%
upside
| Outperform | 9 months ago |
|
14
Scholar Rock
SRRK
$3.12B
| $32.44 | $47 |
45%
upside
| Outperform | 9 months ago |
|
15
Nuvalent
NUVL
$5.74B
| $79.67 | $115 |
44%
upside
| Outperform | 11 months ago |
|
16
Y-mAbs Therapeutics
YMAB
$389M
| $8.57 | $23 |
168%
upside
| Outperform | 11 months ago |
|
17
Oric Pharmaceuticals
ORIC
$1.05B
| $10.77 | $20 |
86%
upside
| Outperform | 11 months ago |
|
|
ORKA
18
Oruka Therapeutics, Inc. Common Stock
ORKA
$561M
| $14.97 | $40 |
167%
upside
| Outperform | 1 year ago |
|
19
Spyre Therapeutics
SYRE
$1.03B
| $16.99 | $45 |
165%
upside
| Outperform | 1 year ago |
|
20
Disc Medicine
IRON
$2.09B
| $60.19 | $57 |
5%
downside
| Outperform | 1 year ago |
|
21
Cogent Biosciences
COGT
$1.81B
| $12.94 | $10 |
23%
downside
| Neutral | 1 year ago |
|
22
Prime Medicine
PRME
$606M
| $3.40 | $12 |
253%
upside
| Outperform | 1 year ago |
|
23
Beam Therapeutics
BEAM
$1.88B
| $18.54 | $57 |
207%
upside
| Outperform | 1 year ago |
|
24
Ultragenyx Pharmaceutical
RARE
$3.01B
| $31.28 | $75 |
140%
upside
| Outperform | 5 years ago |
|